PURPOSE: Preoperative diagnosis of thyroid nodules with "follicular neoplasm" (FN) based on fine-needle aspiration cytology (FNAC) forces thyroidectomy to exclude malignancy. This study explores if (18)F-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG-PET/CT) provides information enough to prevent unnecessary thyroidectomies in this clinical setting. METHODS: This is a prospective study involving 46 consecutive patients scheduled for thyroidectomy due to follicular neoplasm diagnosis in FNAC (36 follicular, 10 Hürthle cell neoplasms, Bethesda classification) since January 2009 until April 2012. All patients underwent preoperative (18)F-FDG-PET/CT. Abnormal (18)F-FDG thyroid uptake was assessed visually and by measuring the maximum standard uptake value (SUV max). Results were compared with definitive pathology reports. RESULTS: Thirteen out of 46 patients (28.3 %) were finally diagnosed with thyroid cancer. Focal uptake correlated with a greater risk of malignancy (p = 0.009). (18)F-FDG-PET/CT focal uptake showed sensitivity, specificity, positive and negative predictive values and overall accuracy of 92.3, 48.5, 41.4, 94.1 and 60.9 %, respectively. The optimal threshold SUV max to discriminate malignancy was 4.2 with an area under receiver-operating characteristic curve of 0.76 (95 % confidence interval, 0.60-0.90). Use of (18)F-FDG-PET/CT could reduce by 13-25 % the number of thyroidectomies performed for definitive benign nodules. However, it has demonstrated worse predictive ability in the subgroup of patients with diffuse uptake, oncocytic pattern in FNAC and lesions smaller than 2. CONCLUSIONS: (18)F-FDG-PET/CT can play a role in the management of thyroid nodules larger than 2 cm cytologically reported as follicular neoplasm without oncocytic differentiation, allowing the avoidance of a significant number of thyroidectomies for definitive benign lesions.
PURPOSE: Preoperative diagnosis of thyroid nodules with "follicular neoplasm" (FN) based on fine-needle aspiration cytology (FNAC) forces thyroidectomy to exclude malignancy. This study explores if (18)F-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG-PET/CT) provides information enough to prevent unnecessary thyroidectomies in this clinical setting. METHODS: This is a prospective study involving 46 consecutive patients scheduled for thyroidectomy due to follicular neoplasm diagnosis in FNAC (36 follicular, 10 Hürthle cell neoplasms, Bethesda classification) since January 2009 until April 2012. All patients underwent preoperative (18)F-FDG-PET/CT. Abnormal (18)F-FDG thyroid uptake was assessed visually and by measuring the maximum standard uptake value (SUV max). Results were compared with definitive pathology reports. RESULTS: Thirteen out of 46 patients (28.3 %) were finally diagnosed with thyroid cancer. Focal uptake correlated with a greater risk of malignancy (p = 0.009). (18)F-FDG-PET/CT focal uptake showed sensitivity, specificity, positive and negative predictive values and overall accuracy of 92.3, 48.5, 41.4, 94.1 and 60.9 %, respectively. The optimal threshold SUV max to discriminate malignancy was 4.2 with an area under receiver-operating characteristic curve of 0.76 (95 % confidence interval, 0.60-0.90). Use of (18)F-FDG-PET/CT could reduce by 13-25 % the number of thyroidectomies performed for definitive benign nodules. However, it has demonstrated worse predictive ability in the subgroup of patients with diffuse uptake, oncocytic pattern in FNAC and lesions smaller than 2. CONCLUSIONS: (18)F-FDG-PET/CT can play a role in the management of thyroid nodules larger than 2 cm cytologically reported as follicular neoplasm without oncocytic differentiation, allowing the avoidance of a significant number of thyroidectomies for definitive benign lesions.
Authors: L S Freudenberg; G Antoch; A Frilling; W Jentzen; S J Rosenbaum; H Kühl; A Bockisch; R Görges Journal: Eur J Nucl Med Mol Imaging Date: 2008-01-12 Impact factor: 9.236
Authors: Jamie C Mitchell; Frederick Grant; Amy R Evenson; J A Parker; Per-Olof Hasselgren; Sareh Parangi Journal: Surgery Date: 2005-12 Impact factor: 3.982
Authors: W Wang; S M Larson; M Fazzari; S K Tickoo; K Kolbert; G Sgouros; H Yeung; H Macapinlac; J Rosai; R J Robbins Journal: J Clin Endocrinol Metab Date: 2000-03 Impact factor: 5.958
Authors: Chandrakanth Are; John F Hsu; Ronald A Ghossein; Heiko Schoder; Jatin P Shah; Ashok R Shaha Journal: Ann Surg Oncol Date: 2007-08-23 Impact factor: 5.344
Authors: Lester J Layfield; Jacki Abrams; Beatrix Cochand-Priollet; Doug Evans; Hossein Gharib; Frank Greenspan; Michael Henry; Virginia LiVolsi; Maria Merino; Claire W Michael; Helen Wang; Samuel A Wells Journal: Diagn Cytopathol Date: 2008-06 Impact factor: 1.582
Authors: Elizabeth J de Koster; Wyanne A Noortman; Jacob M Mostert; Jan Booij; Catherine B Brouwer; Bart de Keizer; John M H de Klerk; Wim J G Oyen; Floris H P van Velden; Lioe-Fee de Geus-Oei; Dennis Vriens Journal: Eur J Nucl Med Mol Imaging Date: 2022-02-09 Impact factor: 10.057
Authors: Kwang Hwi Lee; Dong Wook Kim; Jin Wook Baek; Yoo Jin Lee; Hye Jung Choo; Young Jun Cho; Sun Joo Lee; Young Mi Park; Soo Jin Jung; Hye Jin Baek Journal: Cancer Imaging Date: 2016-10-03 Impact factor: 3.909